BACKGROUND: 1,5-Anhydroglucitol (1,5-AG), fructosamine, and glycated albumin are of increasing interest as alternative measures of hyperglycemia. We characterize the associations of these nontraditional glycemic markers with hemoglobin A 1c (Hb A 1c ) and fasting glucose and assess their ability to identify people with diabetes.
Glucose and hemoglobin A 1c (Hb A 1c ) 3 measurements are central to the diagnosis and management of diabetes. Fasting blood glucose provides an acute assessment of glycemia, whereas Hb A 1c reflects mean glycemic exposure over the preceding 2-3 months (1 ). 1,5-anhydroglucitol (1,5-AG), fructosamine, and glycated albumin are alternative markers of hyperglycemia that can be readily measured in serum and are of increasing interest in research and clinical practice. 1,5-AG is freely filtered by glomeruli, and in the setting of hyperglycemia there is accelerated urinary excretion of 1,5-AG with a corresponding drop in serum concentrations (2 ) . Fructosamine is formed via a nonenzymatic mechanism that involves the binding of blood glucose to serum proteins to form ketoamines (3 ) . Glycated albumin, formed in a similar reaction as fructosamine, is specific to albumin (4 ) . Both fructosamine and glycated albumin increase in the presence of increased blood glucose (3, 4 ) .
There is growing interest in these serum markers as alternatives to fasting glucose or Hb A 1c when these standard measurements are not available, when intermediate glycemic control (1 week to 1 month) is of interest, or in situations that reduce the validity of measurements of fasting glucose (e.g., nonfasting status, diurnal variation, glycolysis, or sample deterioration) or Hb A 1c (e.g., hemoglobinopathies, hemolysis, or altered red cell turnover) (5 ) . However, little is known about the relationships between serum markers of hyperglycemia that are alternatives to Hb A 1c and fasting glucose in the general adult population. Furthermore, in recently reported studies the investigators have assumed a linear relationship between glycemic markers, which may not be a valid assumption (6, 7 ) . The comparative performance of 1,5-AG, fructosamine, and glycated albumin for the identification of persons with diagnosed and undiagnosed diabetes is also unclear.
We undertook this study to characterize the relationships of 1,5-AG, fructosamine, and glycated albumin to Hb A 1c and fasting glucose in persons with and without diabetes and to assess the performance of these serum glycemic markers in identifying cases of diabetes in a community-based population. We hypothesized that these alternative markers would more closely reflect Hb A 1c than fasting glucose, and that nonlinear models may more accurately capture the relationships between established and alternative markers of glycemia as compared to linear models. To investigate whether the associations between the glycemic markers might differ in population subgroups, we examined the correlations within strata of age, sex, coronary heart disease history, hypertension, and chronic kidney disease status.
Materials and Methods

STUDY POPULATION
The Atherosclerosis Risk in Communities (ARIC) study is a community-based prospective cohort of 15 792 adults who have been followed for more than 2 decades. The original ARIC participants were enrolled between 1987 and 1989 from 4 US communities (Forsyth County, NC; Jackson, MS; suburban Minneapolis, MN; and Washington County, MD) (8 -10 ) . In 2004 -2005, 2045 ARIC participants were enrolled in the Carotid Magnetic Resonance Imaging (CARMRI) substudy using a stratified sampling plan. Two-thirds of CARMRI participants were selected because they had a high value of maximum carotid artery intimal medial thickness on ultrasound, and the other third were randomly selected from among ARIC participants with a low intimal medial thickness (11 ) . MRI, physical examinations, laboratory tests, and medical interviews were conducted as part of the CARMRI examination. The present study was limited to the 1719 individuals who participated in the CARMRI examination, who were fasting 8 h or more, and who had valid measurements of Hb A 1c , fasting glucose, 1,5-AG, fructosamine, and glycated albumin.
The study protocol was approved by institutional review boards at each clinical site. Written informed consent was obtained from all participants.
GLYCEMIC MARKERS
Hb A 1c and glucose were measured in 2004 -2005 as part of the original CARMRI protocol on a Roche Hitachi 911 analyzer. Glucose was measured in serum using hexokinase (Roche Diagnostics). Hb A 1c was measured in whole blood using a Tina-quant II immunoassay method (Roche Diagnostics) and calibrated to the Diabetes Control and Complications Trial assay.
In 2009, we measured 1,5-AG (GlycoMark), fructosamine (Roche Diagnostics), and glycated albumin (Asahi Kasei Lucica GA-L; Asahi Kasei Pharma Corporation) in stored serum samples using a Roche Modular P800 system. Glycated albumin was expressed as a percentage of total serum albumin, i.e., 100 ϫ (glycated albumin)/(total albumin). The interassay CVs were: 4.8% (1,5-AG, mean 19.4 g/mL), 3.7% (fructosamine, mean 254.9 mol/L), and 2.7% (glycated albumin, mean 12.8%). Previous studies have demonstrated high stability of these measurements in stored serum samples (12) (13) (14) .
DIABETES
We used 4 definitions of diabetes: Hb A 1c Ն6.5%; fasting glucose Ն126 mg/dL (Ն6.99 mmol/L); a selfreported history of diabetes based on physician diagnosis or glucose-lowering medication use in the last 4 weeks; or a composite definition based on the meeting any of the preceding 3 criteria. Medication use was determined on the basis of a response to a question regarding use of diabetes medications in the 4 weeks before the examination.
OTHER VARIABLES OF INTEREST
All data were collected by trained study personnel using standardized protocols with extensive quality assurance measures, as described previously (11 ) . Age, sex, and race were self-reported. Coronary heart disease was determined with a combination of selfreported history of coronary heart disease and adjudicated coronary heart disease event during active surveillance before the CARMRI visit (10, 15 ) . Hypertension was defined as use of blood pressure-lowering medication and/or a mean of 3 systolic blood pressure measurements Ն140 mmHg (yes or no). We used the Chronic Kidney Disease Epidemiology Collaboration equation (16 ) for estimated glomerular filtration rate (eGFR) from serum creatinine concentration, age, sex, and race. Chronic kidney disease was defined as an eGFR Ͻ60 mL ⅐ min Ϫ1 ⅐ (1.73 m 2 ) Ϫ1 or an albuminto-creatinine ratio Ն30 mg/g (17 ) .
STATISTICAL ANALYSES
Characteristics of the study population were calculated overall and by self-reported history of diabetes. The population quantile distributions of 1,5-AG, fructosamine, and glycated albumin were calculated and compared across age, sex, and race groups. Spearman's correlation coefficients (r) were calculated to describe the relationships between 1,5-AG, fructosamine, or glycated albumin and Hb A 1c or glucose. We compared the correlations overall and stratified by race, history of diabetes, and history of coronary heart disease, chronic kidney disease and/or hypertension. We tested for differences among correlation coefficients with P values obtained by bias-corrected bootstrapping with 1000 replications.
We compared the percentiles across the different glycemic markers and fit regression models to generate corresponding values between the different glycemic markers overall and stratified by diabetes status. We identified the best-fitting models using multiordered, nested polynomials, logarithmic transformations, and inverse transformations. We used the F-statistic to evaluate whether additional terms added useful information to the models. Coefficients of determination were used to evaluate model performance. We visually displayed the associations between markers using scatterplots with overlaid lowess curves.
Finally, we evaluated the ability of 1,5-AG, fructosamine and glycated albumin to identify cases of diabetes by use of the 4 different definitions: Hb A 1c Ն6.5%, fasting glucose Ն126 mg/dL (Ն6.99 mmol/L), self-reported history of diabetes, or any of the preceding 3 definitions. The performance of 1,5-AG, fructosamine, and glycated albumin were compared to the performance of Hb A 1c and fasting glucose where relevant. The weighted area under the curve (AUC) was calculated for each marker and diabetes definition. We calculated CIs for the AUC using bias-corrected bootstrapping with 1000 replications. To examine performance for identifying cases of undiagnosed diabetes, we conducted additional analyses excluding persons currently taking diabetes medications or with a selfreported history of diagnosed diabetes.
All analyses were conducted in Stata 11.1 (StataCorp LP) and were weighted to account for the CARMRI sampling design (11 ) .
Results
Characteristics of the study population overall and by history of diabetes are shown in Table 1 . The mean age of study participants was 70 years. Compared with participants without a history of diabetes, a higher percentage of participants with diabetes were male (48.7% vs 42.1%) or black (33.3% vs 17.5%). Hypertension, a history of coronary heart disease, and chronic kidney disease were more prevalent among participants with diabetes compared with those without a history of diabetes. In this study population, the median eGFR overall was 77.5 mL ⅐ min Ϫ1 ⅐ (1.73 m 2 ) Ϫ1 [interquartile range (IQR): 64.6 -88.5] and the median albumin/ creatinine ratio was 8.5 mg/g (IQR: 5.2-16.7). As expected, mean levels of fasting glucose, Hb A 1c , fructosamine, and glycated albumin were substantially higher in persons with a history of diabetes compared to those without a history of diabetes, whereas 1,5-AG was lower among those with a history of diabetes vs those without a history of diabetes.
We examined the population values of the alternative markers by age, sex, and race (see Table S1 in the Data Supplement that accompanies the online version (18 ) . The different glycemic markers were each strongly associated with age. At older ages, 1,5-AG was lower and fructosamine and glycated albumin were higher.
1,5-AG, fructosamine, and glycated albumin were more strongly correlated with Hb A 1c compared to fasting glucose overall (P values Ͻ0.05) and in subgroups of interest (see online Supplemental Table S2 ). Glycated albumin was more strongly correlated with either Hb A 1c or fasting glucose compared with fructosamine (both P values Ͻ0.05) or 1,5-AG (both P values Ͻ0.05). Similarly, fructosamine was more strongly correlated with either Hb A 1c or fasting glucose than 1,5-AG (both P values Ͻ0.001). Glycated albumin and fructosamine demonstrated similar correlations with fasting glucose, of 0.38 and 0.33 respectively, whereas 1,5-AG showed a weaker relationship (r ϭ Ϫ0.14). Correlations of the serum glycemic markers with Hb A 1c and fasting glucose did not differ substantially across age and race groups; although, 1,5-AG, fructosamine, and glycated albumin were all more highly correlated with Hb A 1c in men than in women. Stronger correlations were observed among persons with a history of diabetes. Correlations were largely similar among subgroups of persons with coronary heart disease, chronic kidney disease, or hypertension. The presence of chronic kidney disease as compared with no chronic kidney disease was associated with a higher Spearman correlation between 1,5-AG and fasting glucose (P ϭ 0.02), but not the other markers. There were higher correlations between glycated albumin and both Hb A 1c and fasting glucose among persons with a history of hypertension, but not 1,5-AG or fructosamine. The overall Spearman correlation between Hb A 1c and fasting glucose was 0.48.
We developed equations to establish the relationships between each serum glycemic marker and Hb A 1c or fasting glucose overall and among persons with and without a history of diabetes (Table 2) . Models had better fit (higher R 2 ) among persons with a history of diabetes. Among persons with a history of diabetes, 1,5-AG, fructosamine, and glycated albumin were more strongly associated with fasting glucose as compared to Hb A 1c . Overall, adopting a nonlinear model improved the R 2 from 0.10 to 0.21 for 1,5-AG and Hb A 1c and from 0.09 to 0.17 for 1,5-AG and fasting glucose, whereas linear and nonlinear models performed comparably for glycated albumin. Similarly, a nonlinear model improved the R 2 for fructosamine and Hb A 1c from 0.39 to 0.46. This is consistent with evidence of nonlinearity seen on the scatter plots and the fitted lowess curves (Fig. 1) .
We provide here corresponding values of Hb A 1c and fasting glucose from the best-fit (nonlinear) models, ordinary least squares linear models, and corresponding weighted percentiles for 1,5-AG, fructosamine, and glycated albumin (see online Supplemental Table S3 ). On the basis of these models, an Hb A 1c value of 6.5% corresponded to 1,5-AG values ranging from 5.0 to 15.3 g/mL, fructosamine values ranging from 254.7 to 289.5 mol/L, and glycated albumin values of 16.1% to 18.3%. A fasting glucose of 126 mg/dL (6.99 mmol/L) corresponded to a 1,5-AG of 5.9 -15.7 g/mL, a fructosamine of 250.5-276.4 mol/L, and a glycated albumin of 15.5%-16.9%.
For all 4 different definitions of diabetes, glycated albumin and fructosamine identified cases of diabetes comparably to Hb A 1c or fasting glucose (Table 3 ). Fructosamine had nonsignificantly smaller AUCs than glycated albumin, whereas 1,5-AG was significantly worse than either fructosamine or glycated albumin. Excluding participants currently using glucose-lowering medication or participants with a history of diabetes each attenuated the diagnostic performance of all the markers.
Discussion
In this study we described the relationships between alternative glycemic markers (1,5-AG, glycated albumin, and fructosamine) and established glycemic markers (Hb A 1c and fasting glucose) in a communitybased population. We observed high correlations for glycated albumin and fructosamine with Hb A 1c and fasting glucose. Glycated albumin was more strongly correlated with Hb A 1c and fasting glucose compared to fructosamine or 1,5-AG. Of the alternative glycemic markers, glycated albumin and fructosamine performed comparably to Hb A 1c and fasting glucose for identifying cases of diabetes in this population, regardless of definition of diabetes used.
1,5-AG is a monosaccharide that is filtered via the glomeruli at a rate of 5-10 g/L each day and has a halflife shorter than fructosamine or glycated albumin (2 ) . In healthy persons, most of the filtered 1,5-AG is reabsorbed by the proximal tubule. However, in states of severe hyperglycemia and glycosuria, glucose in the urine competitively inhibits reabsorption of 1,5-AG, causing increased urinary excretion and a reduction in serum concentrations (2 ). 1,5-AG values are thought to reflect hyperglycemic exposure over approximately a 1-week period (19 ) . This may explain our observation that 1,5-AG was virtually uncorrelated with Hb A 1c (r ϭ Ϫ0.07) or fasting glucose (r ϭ 0.03) in people Table 2 . Best-fit models overall and by history of diagnosed diabetes. without diabetes. Furthermore, the poorer performance of 1,5-AG in identifying diabetes cases is consistent with the fact that 1,5-AG concentrations are substantially lowered only when circulating glucose concentrations are very high (5 ). Fructosamine and glycated albumin are formed by the covalent binding of glucose to serum proteins via a nonenzymatic glycation reaction (3, 4 ) . Whereas fructosamine is a measure of serum ketoamines (3 ), glycated albumin is specific to albumin (4 ). Both of these markers have a half-life of about 17-21 days, reflecting exposure to glucose over the preceding 2-3 weeks (3, 4, 20 -22 ) . In our study we observed very low interassay coefficients (3.7% and 2.7%, respectively), suggesting excellent laboratory performance of the assays implemented in this study. With regard to fructosamine, we observed a stronger correlation with Hb A 1c compared to fasting glucose (r ϭ 0.40 vs 0.33; P ϭ 0.01). Furthermore, fructosamine performed well for the identification of diabetes cases, with AUCs of approximately 0.8 regardless of the diabetes definition used. Our linear model relating fructosamine to Hb A 1c was similar to a previous report in the literature (23 ) . However, our data suggest a nonlinear model may better describe the relationship of fructosamine to Hb A 1c , contrary to previous assumptions (6, 7 ) . Despite the similarities between fructosamine and glycated albumin, glycated albumin was more highly correlated with Hb A 1c and fasting glucose compared to fructosamine. Glycated albumin also outperformed fructosamine and 1,5-AG for the identification of diabetes, performing comparably to both Hb A 1c and fasting glucose.
There are a number of limitations to our study that should be considered in the interpretation of our results. First, the mean age of participants in the CARMRI study was 70 years (range: 60 -84 years) and it is unclear if the same results would be obtained in younger populations. Second, there were only 343 per- Best-fit model equations (from Table 2 sons with diagnosed diabetes in this community-based population. As a result, the distribution of glycemic values available for evaluation of the relationships between markers was limited. In particular, our precision to characterize the interrelationships of these markers at high levels of hyperglycemia was correspondingly low. Additional studies are needed to evaluate the performance in persons with diabetes and across a wide range of glycemic control. Third, we had only single measurements of each glycemic marker and no information on 2-h glucose concentrations (oral glucose tolerance tests were not conducted in the CARMRI Study). Fourth, we had limited power to conduct subgroup analyses. Indeed, our definition of chronic kidney disease was based on single measurements of serum creatinine and albuminuria, and there were few participants in the advanced stages of kidney disease.
This study also had several strengths, including its biracial, community-based population and rigorous assessment of multiple glycemic markers. To our knowledge, this is the largest study comparing fructosamine, glycated albumin, and 1,5-AG to Hb A 1c and fasting glucose in a community-based setting. We have previously shown in this same population that fructosamine, glycated albumin, and 1,5-AG are strongly associated with future diabetes risk, even after adjustment for Hb A 1c or fasting glucose (24 ) .
In conclusion, our results suggest that glycated albumin and fructosamine may be useful as adjunct measures of hyperglycemia to Hb A 1c or in settings where Hb A 1c (or whole blood samples for its measurement) are not available. 1,5-AG may be useful in the setting of overt hyperglycemia. It remains unclear whether these serum glycemic markers may have clinical utility in settings where the performance of Hb A 1c is questionable (e.g., hemoglobinopathies, anemia, or end-stage renal disease). Additional studies are needed to understand the possible roles of all 3 serum markers in diabetes care. In particular, future investigations should evaluate the associations of 1,5-AG, glycated albumin, and fructosamine with clinical complications of diabetes (e.g., microvascular and macrovascular outcomes). 
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